New findings published in a recent New England Journal of Medicine article shows the triplet of daratumumab, lenalidomide and dexamethasone giving 43% of myeloma patients complete response. Daratumumab was approved by the FDA for use in myeloma in November of 2015 and is now being tested in a wide variety of clinical trial combinations. This triple combination was tested in a Phase III trial for myeloma patients who had relapsed or were refractory to treatment.
"The depth of response and the decrease in the risk of progression seen with this combination is unheard of in patients with such advanced disease."
Study author and lead researcher Dr. Meletios Dimopoulos, a professor at the National and Kapodistrian University of Athens, in Greece said:
"It is very likely that (this regimen) will be rapidly adopted by practicing physicians."
To find all clinical trials using daratumumab, click here: Daratumumab Clinical Trials
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).